Avonex-evaluation of Quality of Life and Convenience in Belgian Participants - The AVAIL Study

Biogen

Status: Completed

Conditions: Multiple Sclerosis

Treatments: Drug: Interferon beta-1a

Study type: Observational

Funder types: Industry

Identifiers

NCT01272128

BE-AVO-01

Details and patient eligibility

About

The primary objective is to assess the quality of life of intramuscular (IM) Interferon Beta-1a in participants with relapsing remitting multiple sclerosis (RRMS) or Clinically Isolated Syndrome (CIS) in a clinical practice setting.

Enrollment: 100 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Key Inclusion Criteria:

• Decision to treat with Interferon Beta-1a (IFN beta-1a) must precede enrollment, independently of the study and in compliance with the marketing authorization
• Study enrollment must occur prior to 4th weekly administration of IFN beta-1a
• Able to understand and complete a self-administered questionnaire
• No contra-indications for IFN beta-1a

Key Exclusion Criteria:

• Subjects with history of hypersensitivity to natural or recombinant IFN beta or to any component
• Subjects with primary or secondary progressive MS
• Subjects with current severe depression and/or suicidal ideation
• Pregnant women
• Subjects participating in another clinical trial
• Subjects who do not want to participate in the study

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.